Starting enrollment in November 2008, the recruitment rate decreased significantly during 2011 due to the introduction of BRAF/MEK pathway inhibitors and immune checkpoint blockers for the treatment of advanced metastatic melanoma. Here, MAP2K7 is linked to metastatic melanoma.